Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones

Core Insights - Verve Therapeutics is advancing a new class of genetic medicines targeting cardiovascular disease, with significant milestones expected in 2025 [1][2][3] Pipeline Updates - Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102, targeting PCSK9, is expected in the second quarter of 2025 [1][3] - Dosing in the Heart-2 trial has progressed to the 0.6 mg/kg cohort, with previous cohorts showing no serious adverse events [3][4] - The Heart-2 trial includes patients with heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease (CAD) [3][8] - VERVE-301 has been nominated as a development candidate targeting the LPA gene, with a milestone payment from Eli Lilly expected [1][5][7] Financial Position - Verve is well-capitalized, with cash runway extending into mid-2027, supported by existing cash and expected milestone payments [1][5] Upcoming Events - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 [1][6]